Ispecimen Inc. (ISPC) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Ispecimen Inc. (ISPC) stock forecast summary
Our AI ranks Ispecimen Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Ispecimen Inc. is a small-cap company with a market capitalization of $2M. It ranks number 14 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast.
For ISPC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 34.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ISPC included.
Follow ISPC freeISPC price chart and AI forecast
How ISPC ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Ispecimen Inc. (ISPC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | ISPC | Rank |
|---|---|---|
| Market Cap | $2M | 14/15 |
| P/B Ratio | 1.33x | 8/10 |
| EPS | $-43.64 | – |
| Book Value/Share | $0.69 | – |
Profitability & Margins
| Metric | ISPC | Rank |
|---|---|---|
| Gross Margin | -175.7% | 7/7 |
| Operating Margin | -1641.2% | 12/13 |
| EBT Margin | -1291.7% | 12/13 |
Financial Health
| Metric | ISPC | Rank |
|---|---|---|
| Current Ratio | 0.82x | 8/16 |
| D/E Ratio | 3.26x | 4/11 |
| Financial Leverage | 4.26x | 4/10 |
| Interest Coverage | -1452.9x | 13/13 |
| Working Capital | -$990K | 7/15 |
Cash Flow
| Metric | ISPC | Rank |
|---|---|---|
| Operating Cash Flow | -$11M | 11/15 |
Operational Efficiency
| Metric | ISPC | Rank |
|---|---|---|
| Payables Period | 2089 days | 1/6 |
Income Statement
| Metric | ISPC | Rank |
|---|---|---|
| Operating Income | -$9M | 10/15 |
| SG&A Expense | $5M | 11/12 |
| Cost of Goods Sold | $820K | 7/8 |
Dividend & Shareholder Information
| Metric | ISPC | Rank |
|---|---|---|
| Shares Outstanding | 3M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4M | 60.6% of assets |
| Cash & Short-term Investments | $4M | 59.6% of assets |
| Accounts Receivable | $20K | 0.3% of assets |
| Total Liabilities | $6M | 76.5% of assets |
| Short-term Debt | $810K | 11.0% of assets |
ISPC quarterly financials and insider trading
Ispecimen Inc. (ISPC) industry peers
Companies classified under the same SEC industry code as Ispecimen Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ISPC Ispecimen Inc. | ▼ | $2M |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▶ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where ISPC sits on the market map
Ispecimen Inc. (ISPC) stock news
Loading...
Ispecimen Inc. (ISPC) stock forecast FAQ
What is the Ispecimen Inc. (ISPC) stock forecast?
Our AI ranks Ispecimen Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Ispecimen Inc. stock predictions?
For ISPC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 34.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Ispecimen Inc. forecasts updated?
Ispecimen Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Ispecimen Inc.'s industry peers?
16 issuers in our coverage, ISPC included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.